Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction

European Journal of Heart FailureEarly View Research Letter Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction Ankeet S. Bhatt, Ankeet S. Bhatt Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, CA, USA Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, USA Contributed equally as co-first authors.Search for more papers by this authorMuthiah Vaduganathan, Muthiah Vaduganathan Brigham and Women's Hospital, Heart and Vascular Center, Boston, MA, USA Contributed equally as co-first authors.Search for more papers by this authorBarada Prasad Jena, Barada Prasad Jena Novartis Global Service Center, Hyderabad, IndiaSearch for more papers by this authorSylwia Suminska, Sylwia Suminska Novartis Corporate Center, Dublin, IrelandSearch for more papers by this authorCarlos Eid, Carlos Eid Novartis Pharma Services AG, Office Middle East and North Africa, Nairobi, KenyaSearch for more papers by this authorRahul Khairnar, Rahul Khairnar Novartis Pharmaceuticals Corporation, East Hanover, NJ, USASearch for more papers by this authorGabriella Farries, Gabriella Farries Novartis Corporate Center, Dublin, IrelandSearch for more papers by this authorMichele Senni, Corresponding Author Michele Senni [email protected] Università Milano – Bicocca, Ospedale Papa Giovanni XXIII, Bergamo, Italy Corresponding author. Email: [email protected]Search for more papers by this author Ankeet S. Bhatt, Ankeet S. Bhatt Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, CA, USA Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, USA Contributed equally as co-first authors.Search for more papers by this authorMuthiah Vaduganathan, Muthiah Vaduganathan Brigham and Women's Hospital, Heart and Vascular Center, Boston, MA, USA Contributed equally as co-first authors.Search for more papers by this authorBarada Prasad Jena, Barada Prasad Jena Novartis Global Service Center, Hyderabad, IndiaSearch for more papers by this authorSylwia Suminska, Sylwia Suminska Novartis Corporate Center, Dublin, IrelandSearch for more papers by this authorCarlos Eid, Carlos Eid Novartis Pharma Services AG, Office Middle East and North Africa, Nairobi, KenyaSearch for more papers by this authorRahul Khairnar, Rahul Khairnar Novartis Pharmaceuticals Corporation, East Hanover, NJ, USASearch for more papers by this authorGabriella Farries, Gabriella Farries Novartis Corporate Center, Dublin, IrelandSearch for more papers by this authorMichele Senni, Corresponding Author Michele Senni [email protected] Università Milano – Bicocca, Ospedale Papa Giovanni XXIII, Bergamo, Italy Corresponding author. Email: [email protected]Search for more papers by this author First published: 07 April 2024 https://doi.org/10.1002/ejhf.3233 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Supporting Information Filename Description ejhf3233-sup-0001-Supinfo.docxWord 2007 document , 291.2 KB Appendix S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609–1620. https://doi.org/10.1056/NEJMoa1908655 10.1056/NEJMoa1908655 CASPubMedWeb of Science®Google Scholar 2Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020; 141: 352–361. https://doi.org/10.1161/CIRCULATIONAHA.119.044586 10.1161/CIRCULATIONAHA.119.044586 PubMedWeb of Science®Google Scholar 3Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol 2020; 75: 245–254. https://doi.org/10.1016/j.jacc.2019.11.003 10.1016/j.jacc.2019.11.003 CASPubMedWeb of Science®Google Scholar 4Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: A pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J 2023; 44: 2982–2993. https://doi.org/10.1093/eurheartj/ehad344 10.1093/eurheartj/ehad344 CASPubMedWeb of Science®Google Scholar 5Greene SJ, Triana TS, Ionescu-Ittu R, Shi S, Guerin A, DeSouza MM, et al. Patients hospitalized for de novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol 2021; 77: 1023–1025. https://doi.org/10.1016/j.jacc.2020.12.026 10.1016/j.jacc.2020.12.026 PubMedWeb of Science®Google Scholar 6Savarese G, Hage C, Benson L, Schrage B, Thorvaldsen T, Lundberg A, et al. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: Real-world data from the Swedish Heart Failure Registry. J Intern Med 2021; 289: 369–384. https://doi.org/10.1111/joim.13165 10.1111/joim.13165 CASPubMedWeb of Science®Google Scholar 7Bhatt AS, Vaduganathan M, Claggett BL, Fonarow GC, Packer M, Pfeffer MA, et al. Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiol 2023; 8: 1041–1048. https://doi.org/10.1001/jamacardio.2023.3216 10.1001/jamacardio.2023.3216 PubMedWeb of Science®Google Scholar 8Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895–e1032. https://doi.org/10.1161/CIR.0000000000001063 10.1161/CIR.0000000000001063 PubMedWeb of Science®Google Scholar 9Vaduganathan M, Claggett BL, Greene SJ, Aggarwal R, Bhatt AS, McMurray JJV, et al. Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiol 2021; 6: 1415–1423. https://doi.org/10.1001/jamacardio.2021.3651 10.1001/jamacardio.2021.3651 PubMedWeb of Science®Google Scholar 10McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2024; 26: 5–17. https://doi.org/10.1002/ejhf.3024 10.1002/ejhf.3024 PubMedGoogle Scholar 11Stolfo D, Lund LH, Sinagra G, Lindberg F, Dahlstrom U, Rosano G, et al. Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction. Eur Heart J Cardiovasc Pharmacother 2023; 9: 526–535. https://doi.org/10.1093/ehjcvp/pvad036 10.1093/ehjcvp/pvad036 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation